HONG KONG SAR -  Media OutReach Newswire - 9 June 2026 - DFI Retail Group (DFI or the Group), a leading Asian retailer, and The Mills Fabrica, a global collaborative hub propelling sustainability-focused innovations in the techstyle and agrifood sectors, named Number 8 Bio as the winner of the DFI Sustainability Innovation Challenge 2026. This announcement follows the Final Pitching event, which was held on 5 June, World Environment Day. The Australia-based innovator was recognised for BetterFeed, a range of proprietary feed additives that cut enteric methane from grazing cattle and sheep while improving the productivity of every animal that uses it. The team takes home a HK$120,000 grant and the opportunity to partner with DFI to scale its solution across the Group's regional beef and dairy supply chains.

Scott Price, Group Chief Executive, DFI Retail Group said: "Tackling Scope 3 emissions requires collaboration across the value chain, and we are pleased that the Challenge has created opportunities for innovators to test and scale practical solutions within real operating environments. We look forward to seeing how they support our progress towards more sustainable and resilient food systems."

Meet the Winner: From Pitch to Pilot Across Asia's Supply Chains

Number 8 Bio has built a feed additive that does two jobs at once. BetterFeed, a family of proprietary organic small molecules, free of bromoform, reduces enteric methane from grazing cattle and sheep, which is responsible for both the majority of livestock emissions and a 12% loss of nutritional energy from every pasture. By stopping that methane from forming, BetterFeed redirects the recovered energy straight back into animal growth and production, a genuine win for farmers' bottom lines as much as for the climate. Winning the DFI Sustainability Innovation Challenge opens a pilot pathway across DFI's beef and dairy supply chains, including with Mengniu Dairy and Charoen Pokphand Foods Public Company Limited (CPF).

Thomas Williams, CEO and Co-Founder of Number 8 Bio said, "We are grateful for the exposure to such a high-calibre ecosystem, from fellow innovators addressing the same problem from different angles to the investors and industry players. The conversations alone have accelerated our thinking in ways that months of independent work could not."

A Global Search Anchored in Asia: Addressing the Region's Beef and Dairy Decarbonisation Challenge

Across Asia, rising incomes and urbanisation continue to drive demand for meat and dairy products. Supporting the transition to lower-emission production will be key to ensuring the long-term resilience of food systems while meeting evolving consumer expectations.

Launched in December 2025, the DFI Sustainability Innovation Challenge was designed to bridge innovation and implementation by connecting global innovators directly with DFI's extensive supply-chain network.

Through The Mills Fabrica's global scouting network across 30 countries, including university research institutions, venture capital and startup-incubator networks, the Challenge attracted over 40 submissions from five continents. These solutions ranged from novel feed, feed additives and biomanufacturing to AI and SaaS data platforms, processing innovations and energy management systems. Nearly half were at commercial-ready maturity, reflecting a strong pipeline of scalable solutions rather than early-stage concepts.

Cintia Nunes, General Manager, Head of Asia, The Mills Fabrica said, "The next phase of climate innovation is not just about discovering new technologies but helping them scale in ways that create tangible change. DFI is an industry leader willing to put real supply-chain access and pilot pathways behind climate-tech innovators. We are committed to deepening this partnership with DFI and to working with more forward-looking partners, so that the most promising innovators get the partnerships, capital and pilots they need to translate their work to commercial impact."

Clinicians report less stress, more confidence, safer care

By automating routine tasks and streamlining workflows, AI also reduces emotional and cognitive load for clinicians. Half report less work-related stress (49%) and two-thirds (65%) report greater confidence in decision-making. Notably, 39% have already seen AI identify or prevent potential medical errors at least three times in the past three months.

"Clinicians are beginning to experience AI not as an abstract technology, but as something that meaningfully changes clinical safety," said Ami Bhatt, MD, Chief Innovation Officer, American College of Cardiology.

Many healthcare systems are playing catch-up with AI

While many healthcare professionals report improved workflow efficiency, AI adoption has exposed gaps in organizational readiness. Some healthcare systems are already realizing significant returns, while others struggle to move beyond pilot programs. Integrating AI into care remains complex, particularly where fragmented healthcare IT environments and limited interoperability make it difficult to deploy AI consistently across teams and care settings. These barriers can slow implementation and limit the ability to scale AI effectively in practice.

A majority (59%) of clinicians say their organization's leadership are taking the right steps to implement AI. Yet uneven progress and lack of training expose the untapped opportunity -- 7 in 10 (70%) clinicians report inadequate, inconsistent, or unavailable training. The top training needs include checking the accuracy of AI recommendations developing technical navigation skills and understanding legal liability.

The report findings point to a healthcare sector in transition: AI is already reshaping care, yet adoption varies widely across organizations and care settings. Its impact is transforming care but the next phase depends on effective implementation, integration and support across healthcare systems. Expanding access to the right tools and training, alongside strong clinical leadership, clear governance and organizational support, will be critical to helping clinicians adopt AI confidently and consistently in practice. Ultimately enabling more time for patient care and higher-value clinical work.

Patients are increasingly using AI to support clinician consultations

Clinicians are now working at their best, with 82% seeing or expecting their roles to move to

higher-value activities, and 71% say AI will help them to work at the top of their capabilities. Patients are also considered active partners in their care. Three-quarters (74%) of clinicians report patients arriving at consultations AI-informed and 63% of them regard informed patients as integral future partners in their extended, hybrid team. Over half of patients (56%) predict that AI will help them take a more active role in their care in the future.

"Time savings translate into more than operational efficiencies," said Carla Goulart Peron, Chief Medical Officer at Philips. "Half of the clinicians we surveyed report experiencing less stress and a better work-life balance. Patients experience these benefits directly through higher-quality interactions, the attention they receive during appointments and the time clinicians have to listen. As a clinician, I know that trust is built through human connection, and creating more time for those moments benefits everyone." ***

GaNEXUS addresses these challenges by enabling faster switching speeds, lower switching losses, higher power density, and improved thermal performance compared to conventional silicon-based solutions. These advantages allow customers to reduce the size of magnetics and cooling systems while improving overall system efficiency and responsiveness and lowering system cost in applications ranging from AI data center power delivery and electric vehicle charging to robotics and industrial power systems.

"Our GaNEXUS portfolio is enabling new architectures for power system design," said Antoine Jalabert, vice president of the GaN division at onsemi. "As customers push for more power in less space, it gives engineers greater flexibility to overcome constraints that have limited conventional power architectures."

How it Works: GaNEXUS solutions are engineered to improve how modern power systems convert and manage energy. When paired with onsemi's Treo Platform for integrated sensing, control, protection, and power-management, GaNEXUS can deliver complete system-level power solutions that are smarter, more reliable, and more robust. This system-level approach helps customers simplify design complexity, accelerate development and qualification, reduce thermal and cooling requirements, and optimize performance across the full power delivery chain.

In low- and medium-voltage systems, including AI server 48V intermediate bus converter (IBC) and battery backup units (BBU) and motor drives, GaNEXUS enables:

   * ~30--60% smaller magnetics

   * ~1.5x--2x higher power density

   * ~0.5--2% efficiency improvement, depending on topology

   * Reduced switching losses, improved thermal performance and control stability

In higher-voltage applications such as AI power shelves, high-voltage DC-DC conversion, PFC, and LLC power stages, GaNEXUS enables:

      * Up to ~60% reduction in magnetics size in high-frequency AC-DC and resonant stages

      * ~1.5x--2x higher power density in PFC, LLC, and HV DC-DC architectures

      * ~0.5--1% efficiency gains with meaningful thermal and operating-cost impact at scale

      * Lower losses reduce thermal stress in compact, high-power systems

      * GaNEXUS Smart reduces system risk and simplifies power stage design for faster qualification and higher confidence

GaNEXUS devices feature thermally enhanced packages with industry-standard footprints for dual sourcing, like TOLL Bottom Cooling, TOLT Top Cooling, and dual cooling 3.3mm x 3.3mm and 5mm x 6mm packages.

Additional Information

         * onsemi GaNEXUS

         * onsemi Treo Platform

Bombardier's expanded presence at Seletar Airport -- supported by key regional collaborators, including Singapore's JTC and Economic Development Board (EDB) -- is expected to support the creation of more than 200 highly-skilled jobs over time, contributing to the development of regional growth and aerospace talent. This development -- Bombardier's third in Singapore since 2014 -- further strengthens the company's Singapore Service Centre, building on its position as the region's largest OEM business aviation service facility, by increasing capacity and capabilities to support a greater number of aircraft. The site currently employs over 300 local staff, including approximately 250 licensed engineers and technicians.

Additionally, Bombardier has joined A*STAR Advanced Remanufacturing and Technology Centre's (A*STAR ARTC) industry consortium as an Anchor Member to further strengthen its Maintenance, Repair and Overhaul (MRO) capabilities. This collaboration will accelerate digitalization, AI and automation, enhance operational efficiency, and reinforce Singapore's position as a key aerospace maintenance hub.

"Bombardier's latest expansion will add new MRO and recompletion capabilities for next-generation business aircraft and create 200 new jobs. This investment will further entrench Singapore's status as Asia's premier aerospace hub. The collaboration with A*STAR ARTC on advanced MRO solutions exemplifies how globally leading companies can tap on Singapore's vibrant and trusted ecosystem to drive new innovations in advanced manufacturing that will shape the future of aviation and aerospace," said Cindy Koh, Executive Vice President of EDB.

"Bombardier's expansion reinforces Singapore's position as a leading Business Aviation hub, creating quality jobs and strengthening our aerospace ecosystem. We are pleased that Seletar Aerospace Park continues to enable industry leaders like Bombardier to grow their regional presence, expand their capabilities and deliver high-value services from Singapore," said Christine Wong, Assistant CEO of JTC.

Bombardier's Services business has a strong footprint in APAC, including a service centre in Melbourne, Australia and a jointly owned facility in Tianjin, China. Singapore plays a key role in Bombardier's regional network, hosting one of the company's Customer Response Centres, as well as the company's largest regional parts hub.

With top rankings in both Aviation International News and Professional Pilot Product Support surveys in 2025, Bombardier continues to set the standard for industry-leading service and support. Following the recent entry-into-service of the flagship Global 8000 aircraft, the company remains committed to strengthening its capabilities in key strategic locations to support its global customer base.(1) ***

Accordingly, the Company believes that treating internal disputes or disagreements among certain shareholders as grounds to negate transaction arrangements already undertaken by the Company with registered shareholders lacks a factual basis and may mislead the market and the public. The Company will not disregard the objective facts created by duly executed transaction documents and the actual identity of shareholders based on unilateral statements made by individual members of management or other persons through media, social media, or third-party channels.

IV. The Company Will Continue to Advance Relevant Approvals, Closing Procedures, and Subsequent Integration Efforts in a Lawful and Compliant Manner

The Company reminds investors that the HyalRoute transaction is currently still in the process of advancing through the relevant closing conditions, regulatory approvals, and procedural arrangements contemplated by the transaction agreements. The transaction can become effective and close only after the agreed conditions and applicable regulatory approvals have been satisfied.

The Company will continue to comply with applicable laws, regulations, and listing rules, and will timely fulfill its disclosure obligations with respect to approval progress, closing progress, and other material developments relating to the transaction.

The Company also welcomes other shareholders of HyalRoute, as well as other relevant creditors and debt counterparties, to participate in and support this package equity acquisition arrangement on the same acquisition terms as those set forth in the existing executed transactions. After approximately three years of negotiations, the Company has advanced the relevant equity transactions on the basis of the current transaction terms, including a price of US$10.00 per share and an implied overall valuation of US$4.0 billion for HyalRoute. The Company welcomes all relevant parties and management to maintain rational and constructive communication with the Company, so as to jointly promote the steady advancement of the relevant matters on a lawful, compliant basis and with full respect for shareholder rights.

V. The Company Reserves the Right to Pursue Legal Remedies With Respect to False Statements

With respect to any false statements disseminated through media, social media, or other public channels that are materially inconsistent with the facts and may mislead the market, damage the Company's reputation, or harm investor interests, the Company reserves the right to take all necessary legal measures, including, without limitation, requiring cessation of infringing conduct, demanding clarification of the facts, and pursuing liability in accordance with law.

The Company further reminds all parties that information disclosures by a listed company should be based on the Company's formal announcements, lawfully disclosed filings, and regulatory filings. Investors are advised to carefully assess the source of information, exercise rational judgment, and be mindful of investment risks.***

The second edition of the popular topiary showcase introduces an interactive area starring Disney's Frozen, and more beloved Disney and Pixar character dioramas including Toy Story 5 and Disney Princess

SINGAPORE - Media OutReach Newswire - 8 June 2026 - Disney magic blooms anew at Singapore's premier horticultural destination Gardens by the Bay as the second edition of Disney Garden of Wonder, opens today. Featuring 23 vibrant topiaries inspired by beloved Disney and Pixar characters, the enchanting showcase transforms Floral Fantasy into a world of floral artistry and imagination through 14 March 2027.

Organised in collaboration with Disney and supported by the Singapore Tourism Board, Disney Garden of Wonder is inspired by Disney and Pixar stories that have charmed generations of fans around the world, inviting people of all ages to re-discover their favourite stories of courage, kindness, friendship and love through the beauty of plants. Following the success of its debut at Gardens by the Bay in 2024, the enthralling floral showcase returns in an even more special second edition.

Visitors can look forward to five themed areas:

Frozen, in which topiary versions of Anna, Elsa and Olaf preside over an enchanting snowy landscape, brought to life through themed lighting that imagines a frost-kissed world of wonder. Inspired by Elsa's Ice Palace, visitors can step on a floor where magical snowflakes dance and respond to movement.

Disney princesses, where Rapunzel appears alongside her best friend Pascal the chameleon; Belle is with the Beast and their enchanted companions; and Jasmine is accompanied by her loyal tiger Rajah.

Hundred Acre Wood, where Winnie the Pooh, Eeyore, Piglet and Tigger gather in a cheerful party scene. Tigger bounces up and down while Piglet twirls, and visitors can picture themselves joining everyone at the table!

Toy Story 5, where Woody, Jessie and Buzz Lightyear appear as topiaries in a playful setting inspired by Bonnie's Room, alongside displays of new characters Lilypad and Smarty Pants.

Go Local, a Singaporean-themed zone where Disney characters are reimagined in familiar local settings. Chip 'n Dale perch atop a giant ice cream sandwich; Minnie Mouse and Daisy Duck share the spicy rice noodle dish laksa; and Mickey Mouse makes the traditional beverage teh tarik with Donald Duck.

Outside Floral Fantasy, a 4m-tall Sorcerer's Apprentice Mickey marks the entrance and welcomes visitors to Gardens by the Bay.

The hand-assembled topiaries are crafted from more than 40 species of preserved and dried floral materials, which took more than 16,000 man hours.

Each material was selected for its colour, texture and form, helping to reflect each character's features. Plenty of flowers are used for the Disney princesses for example, while Rapunzel's hair is crafted from Stipa, a perennial grass that has fluffy or oat-like flowerheads.

The surrounding landscapes also use plant palettes that reflect the mood of each zone ? sunflowers and marigolds reflect the honey-toned meadow setting of Winnie the Pooh, while lilies and roses bring out the romantic and jewel-toned settings of Disney Princess stories. Hydrangeas and dusty miller evoke the icy blues, whites and silvers of Frozen.

Throughout the duration of Garden of Wonder, visitors can enjoy select weekend Meet and Greet sessions with Mickey Mouse and Minnie Mouse in outfits inspired by Singapore's national flower, the Vanda Miss Joaquim. Donald Duck and Daisy Duck will also join the experience on select weekends, dressed for a sunny getaway on our tropical island. Meet and Greet dates are available at www.gardensbythebay.com.sg/disneygardenofwonder.

Visitors can round off their experience with shopping at the gift shop, which carries items launching exclusively at Disney Garden of Wonder.

Disney Garden of Wonder

Date: 8 June 2026 to 14 March 2027

Time: 10am to 9pm

Venue: Floral Fantasy at Gardens by the Bay

Details: Tickets are priced at SG$24 for adults and SG$16 for children

Getting here: Take the MRT to Bayfront station. Alternatively, drop off at the Bayfront Plaza carpark via taxi or ride-hailing service. More information available here.

Visit www.gardensbythebay.com.sg/disneygardenofwonder for more details.

Gardens by the Bay

An integral part of Singapore's "City in Nature" vision, Gardens by the Bay is a national garden and premier horticultural attraction that showcases the best of garden and floral artistry for all to enjoy. Spanning 101 hectares in the heart of Singapore's downtown Marina Bay, it comprises three waterfront gardens - Bay South, Bay East, and Bay Central. Bay South, the largest at 54 hectares, officially opened on 29 June 2012.

Guided by the vision to be a world of gardens for all to own, enjoy and cherish, the Gardens' extensive plant collection, ever-changing floral displays, and myriad of engaging programmes have captured the imagination of many, while its Gift of Gardens community initiative, with Mr Tharman Shanmugaratnam, President of the Republic of Singapore as Patron, reaches out to people from all walks of life.

Since opening, Gardens by the Bay has welcomed more than 115 million visitors and garnered numerous international accolades including the third Top Attraction in the World in Tripadvisor Travelers' Choice Awards Best of the Best 2026, Outstanding Achievement in Sustainability at the Singapore Tourism Awards 2024, Best Theme Attraction at TTG Travel Awards 2022 and 2023, and Best Attraction Experience at the Singapore Tourism Awards 2019. The Gardens continues to refresh and refine its offerings, to be a place that everyone can enjoy - a garden where wonder blooms.

For more information, visit www.gardensbythebay.com.sg.

The issuer is solely responsible for the content of this announcement.

Hashtags: #DisneyGardenofWonder #FloralFantasy #GardensbytheBay

-Global Agreement Positions Sportradar as Core Data and Solutions Provider Across Premier Sports Leagues-

- Opportunity to participate across Kalshi ecosystem including market makers and brokers--

ST. GALLEN, Switzerland and NEW YORK, June 08, 2026 (GLOBE NEWSWIRE) -- Sportradar Group AG (NASDAQ: SRAD) today announced a landmark multi-year global agreement with Kalshi, the world's largest prediction market. This strategic agreement positions Sportradar as an official data and solutions provider for Kalshi, delivering a broad portfolio of premium sports content and services across major sports properties including Major League Baseball (MLB), the National Hockey League (NHL), Major League Soccer (MLS), and Ultimate Fighting Championship (UFC), among others.

As prediction markets continue to emerge as a fast growing and regulated segment of the sports ecosystem, Sportradar is positioned to play a foundational role in enabling their growth and facilitating a framework for integrity. This agreement also establishes the ability for Sportradar to enter into agreements directly with Kalshi's key partners, including brokers and market makers, with real time official data and scalable solutions across the value chain.

Sportradar will provide Kalshi with a range of solutions from Sportradar Prediction Services, including:

Official Sports Data and Live Odds: Fast, reliable, accurate official data and live odds to power pre-game and in-play markets, enhancing market efficiency while ensuring timely settlements

Fan Engagement Solutions: Dynamic, real-time content, including scores, schedules, and data visualizations, designed to drive deeper engagement

Customer Acquisition Solutions: Leading marketing services to help acquire high value sports fans

Industry-Leading Integrity Services: Robust integrity framework including Sportradar UFDS AI, which detects suspicious behavior, and Sportradar Integrity Exchange (SIE), which enables participants to share integrity threats through a secure network

The partnership underscores Sportradar's leading position as it extends its core data and premium solutions capabilities into adjacent, high-growth markets. By leveraging its global distribution model and deep relationships, Sportradar continues to broaden its commercial reach while reinforcing its position as critical infrastructure for the evolving sports industry.

Sportradar will provide products and services to Kalshi and other licensed prediction market entities that operate in compliance with applicable regulations and legal requirements.

Carsten Koerl, Chief Executive Officer of Sportradar, said: "Prediction markets represent a compelling growth engine for the global sports ecosystem and Sportradar is uniquely positioned to shape and power this emerging sector. Our partnership with Kalshi extends the reach of our premium sports data and services into a rapidly evolving landscape, fostering collaboration with market makers and the broader marketplace. This partnership with Kalshi marks a critical first step. We look forward to working with key prediction market participants as the landscape matures, establishing the trusted, compliant framework for sports innovation just as we have successfully delivered in online sports betting."

Tarek Mansour, co-founder and CEO of Kalshi, said: "The breadth and depth of this partnership is what makes it a big deal. We're using official league data to ensure quicker trade settlements, creating an overall better customer experience. We're also collaborating on an integrity monitoring program to further protect our users."

Sportradar Group AG

About Sportradar

Sportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports media and betting/gaming industries, Sportradar provides betting and iGaming operators, media and technology companies, prediction market partners and sports federations with a best-in-class range of solutions to help grow their businesses. Trusted by the world's leading global sports organizations including the ATP, NBA and WNBA, NHL, MLB, MLS, PGA TOUR, UEFA, FIFA, CONMEBOL, AFC, and the Bundesliga, and global clients including Flutter, DraftKings, Google, Microsoft and Kalshi, Sportradar covers more than a million events annually across all major sports. Sportradar is not just redefining the sports fan experience, it also safeguards sports through its Integrity Services division and advocacy for an integrity-driven environment for all involved. For more information about Sportradar, please visit www.sportradar.com

About Kalshi

Founded in 2018, Kalshi is the world's largest prediction market. Prediction markets provide accurate, real-time information on the likelihood of events, making humanity more informed about the future. Kalshi is credited with legalizing and establishing prediction markets as a financial asset class. It's the leading safe and regulated platform trusted by millions of people in America. To learn more about Kalshi, visit www.kalshi.com.

CONTACT:

Media:

Sandra Lee

Sandra.lee@sportradar.com

Investor Relations:

Jim Bombassei

j.bombassei@sportradar.com

Elisabeth Diana

ediana@kalshi.com

Copyright 2026 GlobeNewswire, Inc.

New analysis from the IMPACT-TD Registry demonstrates that treatment with AUSTEDO and AUSTEDO XR led to reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, which were associated with improved activities of daily living.

Further data from the 3-year RIM-TD study reinforces the importance of sustained treatment, showing >50% of patients achieve a clinically meaningful response to AUSTEDO by week 15, with additional patients achieving response with continued treatment.

The comprehensive data package presented at Psych Congress Elevate advances clinical understanding of TD from diagnosis to long-term management, underscoring Teva's commitment to improving outcomes for the full spectrum of individuals living with TD.

PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO and AUSTEDO XR. The new findings, drawn from three separate studies, were presented at Psych Congress Elevate, held June 3 - 6, 2026, in Las Vegas, NV.

"The data presented at Psych Congress Elevate represent Teva's pursuit to better understanding the full human experience of tardive dyskinesia," said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "We are dedicated to not only advancing science but also striving to close critical gaps in diagnosis and clinical management of tardive dyskinesia. By generating robust evidence for a broader range of patients, including those with mild TD, and providing insights that guide optimal long-term treatment strategies, we are working to deliver innovations that make a meaningful difference in the day-to-day lives of those living with this condition."

The new findings from Teva's latest research revealed:

Benefit in Mild TD (IMPACT-TD): New real-world insights from the IMPACT-TD Registry, the largest real-world study of TD,1 evaluated patients with mild symptoms who were starting AUSTEDO or AUSTEDO XR treatment. At three months, all participants showed reductions in their Abnormal Involuntary Movement Scale (AIMS) score while maintaining their psychiatric stability; and participants with a clinically meaningful baseline burden in areas such as activities of daily living, psychosocial functioning, speech and communication reported improvement in these domains due to the reduction of TD movements.

Value of Sustained Treatment (RIM-TD): An analysis from the 3-year RIM-TD open-label study found that an increasing percentage of patients responded to treatment over the course of the study. While >50% showed AIMS improvement within 15 weeks, an additional 23% saw improvement after week 15. This underscores the possibility of increasing improvement when patients stay on treatment.

Closing the Diagnosis Gap: A study focused on caregiver education found that providing TD-specific educational content developed in collaboration with patient advocacy groups via online platforms prompted crucial conversations with healthcare professionals. Within six months, 53% of care recipients at risk of TD discussed TD with a provider, and 34% received a TD diagnosis, highlighting an effective strategy to improve disease recognition.

"These findings are significant because they add to the real-world evidence supporting treatment benefit for patients with mild tardive dyskinesia," said Richard Jackson, MD, Assistant Clinical Adjunct Professor at the University of Michigan School of Medicine's Department of Psychiatry and IMPACT-TD principal investigator. "In clinical practice, we know that even so-called 'mild' involuntary movements can have a profound, multidimensional impact on a person's quality of life. These data give clinicians greater confidence to identify and treat TD early, offering the potential to improve outcomes for patients who might have previously been overlooked."

Teva remains deeply committed to advancing the science of tardive dyskinesia and supporting the full needs of the TD community.

About Tardive Dyskinesia (TD)

Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.2,3,4

About AUSTEDO XR Extended-Release Tablets and AUSTEDO Tablets

AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington's disease. Safety and effectiveness in pediatric patients have not been established. AUSTEDO XR is the once-daily formulation of AUSTEDO.

INDICATIONS AND USAGE

AUSTEDO XR (deutetrabenazine) extended-release tablets and AUSTEDO (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington's disease and for the treatment of tardive dyskinesia.

IMPORTANT SAFETY INFORMATION 

Depression and Suicidality in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington's disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression. 

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington's disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.   

Clinical Worsening and Adverse Events in Patients with Huntington's Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects. 

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.  

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.   

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington's disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy. 

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence. 

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.   

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects. 

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington's disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.  Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets. 

Please see accompanying full Prescribing Information, including Boxed Warning. 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as "should," "expect," "anticipate," "estimate," "target," "may," "intend," "plan," "believe" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AUSTEDO and AUSTEDO XR for the treatment of tardive dyskinesia; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-Looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

References:

Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

Carbon M, Hsieh CH, Kane JM, Correll CU. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis. J Clin Psychiatry. 2017;78(3):e264-e278. doi: 10.4088/JCP.16r10832.

Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11.

Tardive dyskinesia. National Alliance on Mental Illness website. https://www.nami.org/Learn-More/Treatment/Mental-Health-Medications/Tardive-Dyskinesia. Accessed May 4, 2026.

Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries TevaIR@Tevapharm.com

Copyright 2026 GlobeNewswire, Inc.